Author: Jane Edwards|| Date Published: August 10, 2016
The International AIDS Vaccine Initiative has received a potential seven-year, $98 million contract from the National Institutes of Health to support the agency™s efforts to develop a vaccine against the disease.
IAVI will work with NIH™s National Institute of Allergy and Infectious Diseases to characterize and produce HIV envelope protein immunogens, IAVI said Tuesday.
NIAID-backed scientists designed such immunogens in order to develop vaccine candidates that work to generate immune response against HIV infection and facilitate the evaluation of such experimental vaccines in human clinical trials.
Mark Feinberg, IAVI president and CEO, said IAVI is pleased to provide product development services to NIAID in support of its AIDS vaccine development initiatives.
IAVI is a two-decade-old nonprofit organization that aims to advance AIDS vaccine research and development programs through collaboration with government agencies, pharmaceutical firms, hospitals and universities in 25 countries.
Nine companies win spots on Navy unmanned systems contract Work covers design, testing, deployment and sustainment support Autonomous maritime platforms…
Anthropic reportedly explores massive new funding round Anthropic deepens focus on AI-driven cyber defense and national security Its growth highlights…
The International AIDS Vaccine Initiative has received a potential seven-year, $98 million contract from the National Institutes of Health to support the agency™s efforts to develop a vaccine against the disease.
